India’s Cipla presses court to not honor Novartis Onbrez patent citing Lupin license deal

EJ Lane

India's argued before the Delhi High against the for its (indacaterol) COPD drug, saying the need not be honored because the Swiss drugmaker was not working it in the country and has licensed it to instead.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS